encequidar
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 30, 2025 (NCT06835400)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- P-glycoprotein 1INHIBITOR
ABCB1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc2c(cc1OC)CN(CCc1ccc(-n3nnc(-c4cc(OC)c(OC)cc4NC(=O)c4cc(=O)c5ccccc5o4)n3)cc1)CC2- Mol. weight
- 688.74 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594298 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06835400 | Phase 3 | Sep 30, 2025 | Government of China |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1